Floatz logo

Tuvonralimab

Carcinoma, Non-Small-Cell Lung

Tianjin Medical University Cancer Institute and HospitalPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

1205 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Tuvonralimab is also rated in:

CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →